Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.

European Cytokine Network. Volume 11, Numéro 1, 91-8, March 2000, Articles originaux

Auteur(s) : D. Blaise, M. Attal, J. Reiffers, M. Michallet, C. Bellanger, J.-L. Pico, A.-M. Stoppa, C. Payen, G. Marit, R. Bouabdallah, J.J. Sotto, J.-F. Rossi, M. Brandely, T. Hercend, D. Maraninchi, Unité de Transplantation et de Thérapie Cellulaire, Université de la Méditerranée, Institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13273 Marseille Cedex 9 France. blaised@marseille.fnclcc.fr.

Mots-clés : acute leukemia, autologous bone marrow transplantation, immunotherapy, interleukin-2, prospective studies.

Illustrations

Figure 1

Leukemia-free survival.

1 = Study arm (N= 65); 2 = Control arm (N = 65).

Figure 2

Leukemia-free survival.

Top Figure (A): Acute myeloblastic leukemia (1 = Study arm (N = 40); 2 = Control arm (N = 38); 3 = patients treated with r-IL-2 (N = 19)).

Bottom Figure (B): Acute lymphoblastic leukemia (1 = Study arm (N = 25); 2 = Control arm (N = 27); 3 = patients treated with r-IL-2 (N = 19)).